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Abstract
Background: Prospective, multicenter, randomized, double-masked trials have shown latanoprost instilled once
daily to be at least as effective as and generally superior to timolol administered twice daily and to be as effective
as other frequently prescribed prostaglandin analogues. This study prospectively assessed the efficacy of
latanoprost monotherapy in a large cohort of treatment-naive patients with a broad range of baseline intraocular
pressure (IOP) levels treated in actual clinical practice settings.
Methods: This prospective, open-label, multicenter, uncontrolled, phase IV study included treatment-naive ocular
hypertension or open-angle glaucoma subjects initiating latanoprost once daily (evening). IOP levels were
measured at baseline and after 1 and 3 months. The primary efficacy outcome was mean change in IOP from
baseline to month 3. Analyses were stratified by baseline IOP: ≥ 20 and <24 mmHg vs ≥ 24 mmHg.
Results: Efficacy analyses (intent to treat) included 572 subjects: 20 to <24 mmHg group, N = 252; ≥ 24 mmHg
group, N = 320. Mean baseline IOP levels were 22.2 ± 0.9 mmHg and 26.7 ± 2.8 mmHg, respectively. At month 3,
significant IOP reductions were seen in both groups (p < 0.0001, within-group differences); reductions were smaller
in the 20 to <24 mmHg group (-6.3 ± 2.4 vs -9.2 ± 3.7 mmHg, respectively; -28.0 ± 10.6% vs -34.1 ± 11.9%,
respectively). An IOP reduction of ≥ 30% from baseline to month 3 was noted in 48.4% and 65.6% of subjects,
respectively (p < 0.0001). At month 3, targets IOPs of ≤ 18 mmHg were achieved by ≥ 70% of subjects in both
groups. Latanoprost was well tolerated with an adverse event profile similar to that reported in the literature.
Conclusions: This “real world” study found once-daily latanoprost to be effective and safe in treatment-naive
ocular hypertension or open-angle glaucoma patients. Patients with baseline IOP levels of 20 to <24 mmHg as well
as ≥ 24 mmHg benefitted from initial latanoprost therapy.
Trial Registration: Trial Registration Number: NCT00647101
Background
Glaucoma is among the leading causes of blindness
worldwide [1], and elevated intraocular pressure (IOP) is
a major risk factor for progression of both ocular hyper-
tension and glaucoma [2]. Reducing IOP prevents or
delays the onset of open-angle glaucoma in patients
with ocular hypertension [3] and slows progression
among those with open-angle glaucoma [4-8].
Treatment to reduce IOP levels commonly begins with
topical ocular hypotensive agents. Among these, latano-
prost, which became available in 1996 and was approved
by the European Agency for the Evaluation of Medicinal
Products as first-line treatment in March 2002, is one of
the most frequently prescribed and has been shown to
be at least as effective as or superior to the beta-blocker
timolol [9-13]. A pooled analysis [13] of data from eight
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which were double-masked) found latanoprost reduced
diurnal IOP levels statistically significantly more than
timolol in a global population of ocular hypertension
and open-angle glaucoma patients (N = 1389). Sub-
group analyses demonstrated that latanoprost was effec-
tive across racial and ethnic groups and resulted in
similar mean diurnal IOP reductions in those with and
without prior ocular hypotensive treatment other than
prostaglandins.
While findings of individual prospective, randomized,
parallel-group, double-maskedc l i n i c a lt r i a l s-t h eg o l d
standard for evaluating new therapies - and pooled ana-
lyses across trials provide convincing evidence of the
efficacy and safety of latanoprost, their designs are
restrictive and do not reflect conditions found in routine
clinical practice settings. In particular, these trials gener-
ally recruited both treatment-naive and previously trea-
ted patients; set strict inclusion and exclusion criteria,
often stipulating that baseline IOP levels be ≥ 22
mmHg; established a washout period for patients under
treatment at screening; and required frequent patient
monitoring. Thus, it remains of interest to prospectively
assess the efficacy of latanoprost monotherapy in a large
cohort of treatment-naive ocular hypertension and
open-angle glaucoma patients with a broader range of
baseline IOP levels treated in actual clinical practice
settings.
The primary purpose of the present study was to con-
duct such an assessment in patients treated in ophthalmol-
ogy practices in France who were followed for 3 months
after being prescribed first-line latanoprost 0.005% admi-
nistered once daily. In order to determine whether
response to latanoprost differs by presenting IOP level, it
was predetermined that analyses would be stratified by
baseline IOP dichotomized as ≥ 20 and <24 mmHg (20 to
<24 mmHg group) vs ≥ 24 mmHg (≥ 24 mmHg group).
The cut point of 24 mmHg was considered to be clinically
relevant and to distinguish roughly between those with
very high vs moderately high IOP levels. The Collaborative
Normal-Tension Glaucoma Study [14] included only
patients with no recorded IOP over 24 mmHg in either
eye at screening.
Methods
Study design
This was a prospective, 3-month, open-label, multicen-
ter, uncontrolled, phase IV study (NCT00647101) con-
ducted in 258 ophthalmology practices in France. The
final protocol and informed consent documents were
reviewed and approved by the Independent Ethics Com-
mittee (Comité Consultatif de Protection des Personnes
se prêtant à une Recherche Biomédicale de Lyon,
France). The study complied with local French laws,
with the International Conference on Harmonization
Guidelines, and with the Declaration of Helsinki Guide-
lines. Written informed consent was obtained from each
subject prior to study enrollment. We certify that all
applicable institutional and governmental regulations
concerning the ethical use of human volunteers were
followed during this research.
Subjects
Eligible subjects were at least 18 years of age and had a
baseline (initial visit) IOP of ≥ 20 mmHg related to a
diagnosis of unilateral or bilateral ocular hypertension
or open-angle glaucoma (primary open-angle glaucoma,
pseudoexfoliation glaucoma, or pigmentary glaucoma)
following a visual field examination. Only subjects who,
in the investigator’s opinion, required initiation of ocular
hypotensive treatment and who had never been treated
for ocular hypertension or open-angle glaucoma were
eligible. In an effort to balance enrollment across IOP
strata, investigators were instructed to enroll one subject
in each stratum before enrolling additional subjects in
either stratum.
Subjects were excluded if they had traumatic, inflamma-
tory, or neovascular glaucoma; had any ophthalmic or sys-
temic disorder, including uncontrolled asthma, that, in the
opinion of the investigator, would prevent study entry;
had a known hypersensitivity to benzalkonium chloride or
any other component of latanoprost; or had participated
in another clinical trial within 30 days prior to the enroll-
ment visit. In addition, women of childbearing potential
who were not using adequate contraceptive methods or
who were pregnant or nursing were not included.
Treatment and assessments
Subjects were assessed for eligibility at the baseline visit.
Demographic information, ocular and medical histories,
and concomitant medications were documented; best-
corrected visual acuity was measured; biomicroscopy,
ophthalmoscopy, an eyelid examination, and fundoscopy
were performed; and stage of open-angle glaucoma was
classified as early, moderate, or severe. A visual field
examination was conducted at baseline or within the
following 1 month unless such an examination had been
conducted during the 6 months prior to baseline. IOP
was measured prior to pupil dilation using an air-pulsed
tonometer (three measurements; mean IOP value used
in analyses) or a calibrated Goldmann applanation ton-
ometer (single measurement).
All subjects were prescribed latanoprost 0.005% to be
instilled once daily in the evening. Other ocular hypo-
tensive medications were prohibited during the study.
Follow-up visits were scheduled after 1 and 3 months of
latanoprost treatment. At each visit, concomitant medica-
tions were recorded, and biomicroscopy, ophthalmoscopy,
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sured at the same time (± 1 hour) as at the baseline visit
and prior to pupil dilation. The same calibrated device
(air-pulsed tonometer or Goldmann applanation ton-
ometer) was used for the same subject at all visits. As at
the baseline visit, three measurements were made for sub-
jects evaluated with an air-pulsed tonometer (mean IOP
v a l u eu s e di na n a l y s e s )a n das i n g l em e a s u r e m e n tw a s
made for those assessed with a Goldmann applanation
tonometer. At month 3, best-corrected visual acuity was
measured and fundoscopy was performed. At the 1 and 3
month visits, subjects were asked a single question about
how often they forgot to take their latanoprost, and
responses were classified as “took every day,”“ rarely for-
got,” and “forgot sometimes.”
All adverse events, whether observed or volunteered,
were recorded at each follow-up visit. The severity of
events (mild, moderate, or severe) and the investigator’s
opinion about whether the event was related to study
drug were recorded. Serious adverse events were defined
as those that were life-threatening, required inpatient
hospitalisation/prolongation of hospitalisation, caused
persistent or significant disability/incapacity, or resulted
in congenital anomaly/birth defect or death. Adverse
events were followed until they resolved or stabilised. As
part of adverse event reporting, investigators were
instructed to question patients concerning whether they
had used any bottle of latanoprost beyond its expiration
date, i.e., for >28 days after opening. Any such extended
use was reported as an adverse event, and the investiga-
tor also documented whether any related clinical pro-
blem had occurred.
Endpoints and analyses
Efficacy analyses used only IOP measurements of one
study eye per subject. If both eyes of a subject were eli-
gible, the eye with the highest IOP at baseline was con-
sidered the study eye; if the baseline IOP was the same
in both eyes, the right eye was considered the study eye.
The primary efficacy endpoint was mean change in
IOP from baseline to month 3. Secondary efficacy end-
points included mean change in IOP from baseline to
month 1; mean percent change in IOP from baseline to
months 1 and 3; percentage of subjects achieving ≥ 10%
and ≥ 30% reductions in IOP from baseline to month 3;
and percentage of subjects achieving target IOP levels of
≤ 21, ≤ 18, and ≤ 15 mmHg at months 1 and 3.
Efficacy analyses were stratified by baseline IOP level
(20 to <24 vs ≥ 24 mmHg) and were conducted in the
intent-to-treat population which included all subjects
who met entry criteria, who instilled ≥ 1d o s eo fs t u d y
medication, and for whom a baseline IOP measurement
and at least 1 on-treatment IOP measurement was
recorded. In efficacy analyses, the last observation
carried forward method was used to impute missing
data. Safety analyses included all subjects who instilled ≥
1 dose of study medication.
The statistical significance of within-stratum changes
in mean IOP levels from baseline to months 1 and 3
was evaluated using paired t tests. The significance of
between-strata differences in frequencies of subjects
achieving prespecified percentage IOP reductions and
target IOP levels was assessed using chi-square tests.
The two-sided significance level was set at the 0.05 level.
Multiple correspondence analyses were performed to
identify factors predicting response to treatment defined
as a ≥ 30% reduction in IOP from baseline to month 3.
Potential predictors included IOP stratum (20 to <24 vs
≥ 2 4m m H g ) ;a g e( < 5 5 ,5 5t o6 5 ,> 6 5y e a r s ) ;g e n d e r ;
ocular hypertension vs open-angle glaucoma; myopia
(>-6 diopters, ≤-6 diopters, no myopia) presence/
absence of diabetes, sleep disorders, use of antihyperten-
sive medication, obesity, and family history of ocular
hypertension or glaucoma; tobacco use within prior year
(yes/no); and compliance (good/poor). Forward stepwise
logistic regression then was used to determine which
potentially significant predictors provided the most
explanatory power with regard to treatment response.
The sample size calculation was based on require-
ments of the multiple correspondence analyses using the
formula N = Πi=1àn(M(i)) where M(i) is the number
of modalities for variable i and n is the number of vari-
ables studied simultaneously. It was determined a priori
that variables reflecting subject and disease characteris-
tics, cardiovascular risk factors, and ophthalmic history
would be entered into analyses. The target number of
subjects to be enrolled was 768.
Results
Study population
Between 22 December 2003 and 16 February 2005, 600
subjects with ocular hypertension or open-angle glau-
coma were enrolled, 270 subjects in the 20 to <24
mmHg group and 330 subjects in the ≥ 24 mmHg
group (Figure 1). In all, 590 subjects received ≥ 1d o s e
of latanoprost and were included in safety analyses (20
to <24 mmHg group, N = 262; ≥ 24 mmHg group,
N = 328). The ITT population, which excluded 2 sub-
jects who did not meet study entry criteria and 16 for
whom no valid postbaseline IOP measurement was
recorded, included 252 subjects in the 20 to <24 mmHg
group and 320 subjects in the ≥ 24 mmHg group. In all,
553 subjects completed the study; the major reasons for
premature withdrawal among the 590 treated subjects
were adverse events and “other reasons” (n = 13/37 and
n = 11/37, respectively; Figure 1).
Demographic and clinical characteristics of subjects at
baseline are summarized in Table 1. The mean age of
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approximately 59 years; a larger percentage of those in
the ≥ 24 mmHg group were male. More subjects in the ≥
24 mmHg group were diagnosed with open-angle glau-
coma, and, among those with glaucoma, a larger percen-
tage in that group had disease classified as “severe.”
Exposure to latanoprost was similar between groups:
93.1 ± 22.0 days in the 20 to <24 mmHg group and
91.6 ± 18.3 days in the ≥ 24 mmHg group. The majority
of subjects reported high levels of compliance with
once-daily latanoprost, with 98% in each group report-
ing that they took the medication either every day or
that they “rarely” forgot.
Efficacy
At month 3, mean IOP levels had decreased from base-
line by -6.3 ± 2.4 mmHg in the 20 to <24 mmHg group
and by -9.2 ± 3.7 mmHg in the ≥ 24 mmHg group (p <
0.0001 for each within-group comparison; Table 2).
Mean IOP levels decreased rapidly from baseline to
month 1 and remained stable through month 3 with
percent IOP changes of -27.8 ± 10.3% and -28.0 ±
10.6%, respectively, in the 20 to <24 mmHg group and
-32.9 ± 10.6% and -34.1 ± 11.9%, respectively, in the ≥
24 mmHg group.
Similarly large percentages of subjects achieved ≥ 10%
IOP reductions from baseline to month 3 in both
groups: 94.1% in the 20 to <24 mmHg group and 96.9%
in the ≥ 24 mmHg group (p = 0.10; Table 2). A signifi-
cantly smaller percentage of those in the 20 to <24
mmHg group achieved IOP reductions of ≥ 30% by
month 3 (48.4% vs 65.6%, respectively; p < 0.0001). In
contrast, significantly smaller percentages of those in the
higher IOP group achieved IOP levels ≤ 21, ≤ 18, or ≤
15 mmHg at either months 1 or 3 (p < 0.001 for each
between-group comparison; Figure 2). It is notable that
70% of subjects in the ≥ 24 mmHg group achieved IOP
levels of ≤ 18 mmHg by month 3.
Figure 1 Subject disposition.
Denis et al. BMC Ophthalmology 2010, 10:4
http://www.biomedcentral.com/1471-2415/10/4
Page 4 of 9Predictors of treatment response
Initial multiple correspondence analyses of the full vari-
able set identified six potential predictors of response to
treatment (IOP reduction ≥ 30% between baseline and
month 3): age, gender, initial IOP stratum, current diag-
nosis, family history of ocular hypertension or glaucoma,
and myopia. The logistic regression model with 568 sub-
jects retained only two of these variables: initial IOP
stratum and myopia. Treatment response was less likely
in subjects whose baseline IOP was 20 to <24 mmHg
(adjusted risk ratio [95% confidence interval [CI], 0.488
[0.346, 0.686]; p < 0.001) and less likely in those with
myopia (≤-6 diopters vs none: adjusted risk ratio [95%
CI]: 0.576 [0.391, 0.894]; p = 0.0053 and >-6 diopters vs
none: adjusted risk ratio [95% CI]: 0.392 [0.175, 0.879];
p = 0.0230).
Safety
Among the 590 subjects in the safety population, 237
(40.2%) reported ≥ 1 adverse events. Adverse event pro-
files were similar in subjects in the two baseline IOP
strata (Table 3). Note that 119/339 (35.1%) adverse
events and 119/235 (50.6%) treatment-related adverse
events reflected subject report of latanoprost instillation
from a bottle that had been opened for >28 days, which
was documented as an adverse event; no ocular or sys-
temic adverse event associated with use of latanoprost
from an expired bottle was reported. In all, nine subjects
reported 10 serious adverse events, none of which was
considered related to study drug. No deaths were
reported during the study.
The most frequent treatment-related ocular adverse
event was conjuctival hyperemia, occurring in 10.7%
(28/262) and 8.5% (28/328) subjects in the 20 to <24
and ≥ 24 mmHg groups, respectively (Table 4). Eye pain
occurred in approximately 3% of subjects in each IOP
stratum, and all other treatment-related ocular adverse
events occurred in <2% of subjects.
Discussion
Short-term, prospective multicenter, randomized, dou-
ble-masked trials have shown latanoprost instilled once
daily to be at least as effective as and generally superior
Table 1 Baseline demographic and clinical characteristics,
ITT population*
Baseline IOP
Characteristic 20 to <24 mmHg
N = 252
≥ 24 mmHg
N = 320
Age, years
Mean ± SD 59.9 ± 12.2 59.1 ± 11.8
Gender, male 117 (46.4) 174 (54.4)
Diagnosis
Ocular hypertension 150 (59.5) 161 (50.3)
Open-angle glaucoma 102 (40.5) 159 (49.7)
Open-angle glaucoma grade
†
Mild 77 (75.5) 96 (60.4)
Moderate 21 (20.6) 43 (27.0)
Severe 4 (3.9) 20 (12.6)
Intraocular pressure
Mean (SD) 22.2 ± 0.9 26.7 ± 2.8
Family history of ocular
hypertension or glaucoma 85 (33.7) 73 (22.8)
Body mass index
Mean (SD) 25.0 ± 3.9 25.1 ± 3.9
Comorbidities
‡
Diabetes 17 (8.7) 33 (13.3)
Hypertension 69 (35.2) 77 (30.8)
Sleep disorders 39 (19.8) 34 (13.7)
Myopia 78 (31.0) 95 (29.7)
<-12 diopters 1 (1.3) 3 (3.2)
Between -6 and -12 diopters 9 (11.5) 13 (13.7)
>-6 diopters 68 (87.2) 79 (83.2)
Tobacco use within prior year
§ 55 (28.1) 83 (33.3)
*n (%) unless otherwise noted.
†Percentages based on number of subjects with open-angle glaucoma.
‡Percentages based on number of subjects reporting presence/absence of
comorbidities.
§Percentages based on numbers of subjects reporting use/no use of tobacco
within prior year.
ITT = intent to treat; SD = standard deviation.
Table 2 Intraocular pressure (IOP) at baseline and month
3 (mmHg), ITT population
Baseline IOP
20 to <24
mmHg
N = 252
≥ 24 mmHg
N = 320
Baseline IOP, mmHg
Mean ± SD 22.2 ± 0.9 26.7 ± 2.8
Month 3 IOP, mmHg
Mean ± SD 16.0 ± 2.3 17.5 ± 3.2
IOP change from baseline to month 3,
mmHg
Mean ± SD -6.3 ± 2.4 -9.2 ± 3.7
p-value* <0.0001 <0.0001
% change in IOP from baseline to
month 3
Mean ± SD -28.0 ± 10.6 -34.1 ± 11.9
≥ 10% IOP reduction from baseline to
month 3
n (%)
† 237 (94.1) 310 (96.9)
≥ 30% IOP reduction from baseline to
month 3
n (%)
‡ 122 (48.4) 210 (65.6)
*p-value based on t test for paired data.
†p = 0.10 for between-group difference; chi-square test.
‡p < 0.0001 for between-group difference; chi-square test.
ITT = intent to treat; SD = standard deviation.
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effective and as safe as other frequently prescribed pros-
taglandin analogues [15-17]. In an observational study
[18] of patients switched to latanoprost from previous
glaucoma therapies, mean IOP was reduced from 21.3 ±
4.1 to 17.6 ± 3.2 mmHg in 1376 individuals followed for
2 years; the most common ocular adverse event was
ocular irritation, noted in 1.6% of patients, while hypere-
mia was reported in 0.3%. A 5-year, open-label, safety
surveillance study [19] included 5854 patients on IOP-
reducing therapy other than latanoprost who required a
change in therapy and who were randomly assigned to
latanoprost or usual care (any other commercially avail-
able ocular hypotensive therapy). In both groups, serious
adverse drug reactions were reported in approximately
0.4% of patients, and new occurrences of corneal ero-
sions, iritis/uveitis, and macular edema were rare (risk ≤
3.2% for each).
The present prospective, observational study extends
these findings to “real world” treatment -naïve patients.
We found first-line treatment with latanoprost to be
effective and safe in ocular hypertension and open-angle
glaucoma patients with pretreatment IOP levels in both
the 20 to <24 mmHg range and ≥ 24 mmHg. Treatment
response was rapid, seen within 1 month of initiating
therapy, and was maintained throughout the follow-up
period.
As would be expected, absolute and percentage IOP
reductions were greater in the higher IOP stratum.
Others [13,20-22] have observed that higher baseline
Figure 2 Subjects achieving prespecified mean intraocular pressure (IOP) levels at months 1 and 3 *p ≤ 0.001 for between-group
difference.
Table 3 Summary of adverse events, safety population (N = 590)*
Baseline Intraocular Pressure
Subjects with: 20 to <24 mmHg N = 262 ≥ 24 mmHg N = 328
≥ 1 adverse event
† 111 (42.4) [159] 126 (38.4) [180]
≥ 1 treatment-related adverse event
† 83 (31.7) [109] 99 (30.2) [126]
≥ 1 serious adverse event 5 (1.9) [5] 4 (1.2) [5]
≥ 1 adverse event leading to treatment discontinuation 5 (1.9) [7] 8 (2.4) [13]
*n (%) of subjects [number of events].
†Patient-reported use of a bottle of latanoprost beyond its expiration date, i.e., for >28 days after opening, was reported by 54 subjects in the 20 to <24 mmHg
group and by 65 subjects in the ≥ 24 mmHg group. These were counted as adverse events and as treatment-related adverse events. No other ocular or systemic
adverse event was associated with extended use in any subject.
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perhaps in part, due to regression to the mean, the ten-
dency for an extreme value at first measurement to be
closer to the center of the distribution at later measure-
ment time points [23]. Nevertheless, significant
responses to latanoprost therapy were seen in both IOP
strata. For example, IOP levels ≤ 18 mmHg were
achieved by 90% and 70% of patients in the 20 to <24
and ≥ 24 mmHg groups, respectively, at month 3, and
treatment response (≥ 30% IOP reduction from baseline
to month 3) was observed in nearly one half and in
two-thirds of patients, respectively. In this population of
treatment-naïve patients, the percentage of responders
in both groups was greater than the 30% which gener-
ally could be expected with prostaglandin monotherapy
[24]. Moreover, more than 94% of patients in each stra-
tum achieved ≥ 10% IOP reductions from baseline to
month 3, a result consistent with that of a pooled-analy-
sis of eight studies that found IOP reductions of >15%
in 93% of glaucoma and ocular hypertension patients
without prior glaucoma treatment other than prosta-
glandins after 3 to 6 months of latanoprost therapy [13].
In the multivariate model, IOP stratum and myopia
were found to significantly predict treatment response
while other candidate variables including age, gender,
diagnosis, and family history did not. The predictive
value of IOP stratum reflects the positive relationship
between baseline IOP level and IOP reduction discussed
above. It has been suggested that IOP reductions asso-
ciated with latanoprost use could be greater in myopic
eyes since a larger area of trabecular meshwork might
be found in eyes with negative spherical equivalence
[13]. We cannot explain our opposite finding that myo-
pia was negatively associated with a treatment response.
It is possible, however, that the relatively low proportion
of patients in the higher myopia categories affected the
results. Multivariate analyses in populations with a more
even distribution of patients with myopia are needed.
As reported by previous researchers [9-13,15], latano-
prost was safe and well tolerated with no important dif-
ferences between IOP strata. Conjunctival hyperemia
was the most frequently reported ocular adverse event,
occurring in 9% of patients overall. In general, hypere-
mia is the most common adverse event associated with
prostaglandin use [25-27].M o r et h a no n et h i r do f
adverse events overall and one half of treatment-related
adverse events reflected patient reports of instillation of
latanoprost from bottles that had been opened for
>28 days.
Previous research has demonstrated that substantial
reductions in IOP levels [6-8,28] and, in particular,
reductions to levels of <18 mmHg [5] delay or stop
glaucomatous progression. For example, the Collabora-
tive Initial Glaucoma Treatment Study [8] found that
aggressive medical treatment resulting in diurnal IOP
reductions of ≥ 35% from baseline virtually halted glau-
comatous progression over 5 years, and treated patients
in the Early Manifest Glaucoma Trial [7] had half the
progression risk of untreated patients. Based on such
findings, clinicians are encouraged when making treat-
ment decisions to consider the likelihood of achieving a
predetermined target IOP level or percentage IOP
reduction consistent with the patient’s disease status
[24,29].
The relative convenience and side effect profiles of
therapies also may be important factors in treatment
decision making. More complex medication dosing
schedules have been shown to negatively impact adher-
ence in glaucoma patients [3,30-32]. Patients in the pre-
sent study reported very high levels of treatment
compliance with latanoprost. Although these compliance
rates may to some extent reflect ‘white-coat adherence’
[33,34], patients prescribed once-daily prostaglandin
analogues have been found to be more compliant [35]
and to remain on treatment significantly longer [36-38]
than those prescribed other classes of medication,
including beta-blockers. Moreover, patients prescribed
latanoprost are more persistent with therapy than those
prescribed either bimatoprost or travoprost [37]. Ocular
adverse events, especially hyperemia which is less com-
mon with latanoprost than with the other prostaglandin
analogues, have been shown to negatively impact patient
continuation with therapy [39].
The present study has a number of important
strengths. First, findings of this prospective, open-label,
uncontrolled, observational study better reflect actual
clinical practice conditions than those based on rando-
mized, controlled trials and therefore may be more gen-
eralizable to routine ophthalmology practices. Although
the target of enrolling 768 subjects was not reached, the
Table 4 Number (%) of treatment-related ocular adverse
events (N = 590)
Baseline Intraocular Pressure
Subjects with: 20 to <24 mmHg
N = 262
≥ 24 mmHg
N = 328
Hyperemia 28 (10.7) 28 (8.5)
Eye pain 8 (3.1) 11 (3.4)
Blepharitis 3 (1.2) 1 (0.3)
Eyelid pruritis 3 (1.2) 1 (0.3)
Eye abnormality NOS 2 (0.8) 2 (0.6)
Keratitis 2 (0.8) 2 (0.6)
Eyelid edema 0 3 (0.9)
Photophobia 1 (0.4) 0
Vision abnormal NOS 0 1 (0.3)
Xerophthalmia 0 1 (0.3)
NOS = not otherwise specified.
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makes this, to our knowledge, the largest study of the
effectiveness and safety of first-line latanoprost con-
ducted to date. An additional strength is the study’s
inclusion of a multivariate model to evaluate potential
predictors of treatment response.
The study’s limitations include the fact that some
investigators measured IOP levels using air-pulse tono-
metry while others used Goldmann applanation tonome-
try; ideally, all would have used the latter method. The
relative infrequency of presentation by treatment-naive
ocular hypertension or open-angle glaucoma patients to
clinical practices necessitated the inclusion of a large
number of centers to ensure timely subject recruitment;
the impact on findings of interpractice variation in
recording information and/or in treatment standards
and practices is not known. Reflecting the study’s obser-
vational, “real world” approach, investigators did not
routinely record all variables of potential interest, such
as central corneal thickness. In addition, the method
used to measure IOP levels was not always documented
making it infeasible to analyze IOP changes stratified by
tonometry type. Finally, future research should include a
larger population of treatment-naïve patients followed
over a longer time period in order to ensure detection
of rare but potentially serious adverse events; it is nota-
ble, however, that a large 5-year safety study [19] found
rates of new cases of corneal erosions, iritis/uveitis, or
macular edema to be low and similar in those treated
with latanoprost or other approved ocular hypotensive
therapies. A study with a larger patient population also
would support an analysis of risk factors for nonre-
sponse to latanoprost.
Conclusions
This 3-month, open-label, multicenter, uncontrolled,
phase IV, “real world” study found monotherapy with
once-daily latanoprost to be effective and safe in treat-
ment-naive ocular hypertension or open-angle glaucoma
patients. Patients with baseline IOP levels of 20 to <24
mmHg as well as ≥ 24 mmHg benefitted from initial
latanoprost treatment.
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